No recent analyst price targets found for PAYD.
Latest News for PAYD
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PAYD.
U.S. House Trading
No House trades found for PAYD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.